In August 2018, the first-ever RNAi-based drug, Alnylam’s Patisiran, was approved by the U.S. Food and Drug Administration (FDA) for treating transthyretin amyloidosis by inhibiting hepatic transthyretin production [11]. The gene discussed is TTR; the disease is amyloidosis.